Articles tagged with Prostate Cancer
A high-fat diet accelerates prostate cancer growth and increases immune cells that suppress the immune system. Anti-inflammatory drugs may have benefits for obese patients with prostate cancer.
The RESPOND study will explore the role of social stressors and genetics in developing prostate cancer among African-American men. The study aims to recruit 10,000 participants nationwide to understand the factors contributing to poor outcomes in this disease.
Football training has been linked to improved bone mineral density in elderly men with prostate cancer, particularly in those undergoing androgen deprivation therapy. The study found no association with body composition or physical functioning.
A new study found that a deadlier subtype of metastatic prostate cancer, called t-SCNC, constitutes about 17% of resistant cases. Researchers suggest that targeted drugs already in clinical trials could be effective in treating this subtype.
A new study published in European Urology found that high-intensity focused ultrasound (HIFU) treatment is as effective as surgery or radiotherapy in treating prostate cancer, with lower risks of side effects. After five years, the cancer survival rate from HIFU was 100%, comparable to surgery and radiotherapy.
Men treated with ICSI for infertility have a significantly higher risk of developing early-onset prostate cancer, which is considered more aggressive. The study found that this risk is associated with male sub-fertility, not the ICSI procedure itself.
A new form of immunotherapy has been found to reactivate the response to hormone treatment in advanced prostate cancer, a study in mice and human prostate cancer cells has found. The drug blocks a protein produced by immune cells, restoring sensitivity to hormone therapy and potentially improving outcomes for men with advanced disease.
Researchers found improved quality of life and reduced tumor spread in patients treated with LuPSMA therapy. PSMA PET imaging demonstrated exceptional responses, correlating with significant reductions in PSA levels.
Researchers discovered a molecular inhibitor that could help fight prostate cancer when resistance develops to CDK4/6 inhibitors. The study found that tumors become more aggressive and dependent on the MAPK-6 pathway when resistance occurs, making MEK inhibitors a potential therapeutic option.
A study presented at the SNMMI Annual Meeting found that early treatment of advanced prostate cancer with lutetium-177 radioligand therapy can significantly prolong life, with a median overall survival of 27 months. Patients who received first-line therapy also had the longest survival rates.
A clinical trial found that 59% of patients with biochemical recurrence of prostate cancer had their clinical management changed by fluciclovine PET/CT imaging. The study detected disease in the prostate, pelvic lymph nodes, and less commonly, bone, guiding treatment decisions for men with recurrent prostate cancer.
A study investigating combination checkpoint immunotherapy in lethal advanced prostate cancer revealed that genetic subsets of patients with AR-V7+ prostate cancer may benefit from treatment. One-quarter of patients achieved an objective response, and at least two remain alive for over 18 months.
Researchers at Cleveland Clinic found that a common prostate cancer drug, abiraterone, yields high levels of a testosterone-like byproduct in men with advanced disease who have a specific genetic variant. This byproduct may trick androgen receptors into turning on pro-cancer pathways.
Two Phase I/II clinical studies, PROter and PROfind, evaluate the safety and efficacy of radiolabeled PSMA-R2 for prostate cancer treatment. The trials assess tumor activity and patient response to treatment.
Researchers identified a new subtype of prostate cancer characterized by loss of the CDK12 gene, which was found to be more common in metastatic cases. Tumors with this alteration were responsive to immune checkpoint inhibitors, a type of immunotherapy treatment.
A new study found that a pattern of genetic changes in prostate tumours can predict which men are likely to benefit from immunotherapy. The research identified a distinct group of men with advanced prostate cancer whose tumours have biological features that make them responsive to immunotherapy drugs.
Researchers have discovered 63 new genetic variations associated with higher risk of prostate cancer, enabling early and regular screening for men at increased risk. The findings represent the largest increase in genetic markers since their first identification in 2006.
Researchers identified 63 new genetic markers associated with prostate cancer risk in a global DNA analysis of over 140,000 men. The findings suggest that one percent of at-risk men are six times more likely to develop prostate cancer, highlighting the potential for genetic screening and prevention strategies.
A new DNA test has identified 63 genetic variations that increase the risk of prostate cancer, with men inheriting these variants having a 5.7 times higher risk. The test combines multiple genetic variants to predict individual risk, offering hope for early detection and prevention.
A new sensor detects prostate cancer cells in blood samples with high efficiency, using a low-cost method that resembles Velcro. The device captures tumor cells from circulation, enabling doctors to diagnose the disease earlier and monitor its effectiveness.
A study of nearly 10,500 US prostate cancer patients found that more frequent PSA monitoring did not improve long-term survival rates. The research suggests that once-a-year monitoring may be sufficient for most patients.
According to a new analysis of over 8,000 patients, African-American men with advanced prostate cancer who received docetaxel-based therapies had a lower risk of death than white men. This finding is significant, as it challenges the long-held notion that racial disparities in prostate cancer survival are due to biological differences.
African-American men with advanced prostate cancer respond better to anti-androgen drugs and steroids than white men, according to a Duke University Medical Center study. The study suggests potential strategies for improving survival rates among black patients.
A new study found that men with prostate cancer who experience urinary, bowel, or sexual dysfunction after treatment are more likely to experience emotional distress, which can lead to worsening function. The researchers emphasize the need for greater investment in psychosocial care to mitigate treatment side effects and improve qualit...
Researchers found that activating olfactory receptor OR51E2 in prostate cancer cells causes aggressive castration-resistant disease, suggesting a new treatment approach. Blocking the receptor with specific molecules or scents could provide a new way to treat prostate cancer.
A novel long non-coding RNA, ARLNC1, controls signals from the androgen receptor, a key player in prostate cancer. Knocking down this RNA led to cancer cell death, suggesting it as a potential target for future therapies.
A study found that androgen deprivation therapy prolongs QTc interval duration, increasing risk of arrhythmia and sudden cardiac death in men with prostate cancer. Researchers urge oncologists to monitor QTc interval in patients receiving ADT.
A new study reveals declines in prostate cancer screening and diagnoses in the US between 2008-2014, with significant decreases in definitive treatments. The findings suggest that men are choosing active surveillance for low-risk prostate cancer, avoiding treatment-related harms.
A landmark study has delivered a final verdict on finasteride's impact on prostate cancer, finding it reduces risk without increasing mortality. Finasteride significantly lowers the risk of developing prostate cancer without causing an increased risk of dying from the disease.
A new blood test called IsoPSA has been shown to be more accurate in predicting overall risk of prostate cancer than standard PSA tests. The study found that nearly 40 percent of biopsies could have been avoided with the use of IsoPSA, potentially lowering overtreatment rates and reducing unnecessary procedures.
A new software tool called the automated bone scan index (aBSI) has been shown to be both accurate and speedy in calculating how extensively bones have been infiltrated by prostate cancer. The aBSI technology provided prognostic information about patient outcomes, including survival time and symptom progression.
A new study published in Urologic Oncology suggests that MRI fusion biopsy is a more effective method for detecting clinically significant prostate cancer in patients with prior negative biopsies. The study analyzed data from over 700 patients and found that fusion biopsy detected 30.7% of clinically significant cancers, compared to 4....
A study by NYU Langone Health and the VA found that increasing numbers of veterans with non-aggressive prostate cancer are opting for watchful waiting or active surveillance. This shift towards more conservative treatment reflects a reversal in decades-long overtreatment, bringing care more in line with best practice guidelines.
Researchers at University of Bath discovered a link between molecule 'oiliness' and potency against prostate cancer protein AMACR. The team designed test to measure activity levels and identified promising molecules that could lead to new anti-cancer drugs.
Researchers developed a method to identify men with locally advanced prostate cancer who are less likely to respond well to radiotherapy. A 28-gene signature accurately identifies hypoxic tumour tissue in patients with prostate cancer that invades nearby structures. This signature could lead to improved treatment outcomes for patients.
Research in Molecular Oncology reveals overexpression of interleukin-6 (IL6) in tumor-adjacent tissues among African-American men. This leads to inhibition of p53 tumor suppressor protein and promotes self-renewal of cancer cells.
The USPSTF recommends that men aged 55 to 69 consider discussing the benefits and harms of PSA-based screening with their doctor. Screening offers a small benefit of reducing prostate cancer death, but also potential harms like false positives and overdiagnosis.
Analysis of hundreds of human prostate tumors revealed that the most aggressive cancers depend on a built-in cellular stress response to put a brake on their own hot-wired physiology. Experiments showed that blocking this stress response causes treatment-resistant cancer cells to self-destruct while leaving normal cells unaffected.
A new web-based support programme offers online cognitive behavioural therapy and peer support to survivors of prostate cancer, aiming to improve their mental health. The programme has shown promising results in reducing distress and improving quality of life among men recovering from the disease.
Researchers developed a composite score to identify census tracts with high prostate cancer burden, considering incidence and mortality rates. The tool helps pinpoint clusters of high-risk areas that don't always align with demographics, highlighting the need for further study on underlying factors contributing to poor outcomes.
Researchers found a significant link between exposure to blue light at night and higher risks of developing breast and prostate cancer. The study used images taken by astronauts to evaluate outdoor lighting in Madrid and Barcelona.
Researchers found patients in the Prostate Cancer Intervention versus Observation Trial (PIVOT) to be up to eight times more likely to die than real-world patients. The study's patient population was also older and sicker, with an average age of 67 at diagnosis.
Researchers found that ultrahypofractionated radiotherapy is just as effective as standard radiotherapy in stopping prostate cancer from returning, with no significant long-term side effects. Patients treated with this method spend less time traveling to and from hospital for treatment.
Researchers analyzed 293 localized prostate cancer tumors and found that those with multiple types of cancer cells were the most aggressive. The study's findings can help determine the best approach for each individual patient, including sparing patients from unnecessary treatment.
Researchers at Duke University Medical Center have developed man-made aptamers that target prostate cancer cells, killing them while leaving healthy tissue unscathed. The findings suggest that these molecules could form the basis of new cancer therapies if further studies bear out.
A new study presents contrast-enhanced subharmonic imaging (SHI) as a promising tool for detecting prostate cancers not identified by MRI. SHI provides improved contrast signal and tissue suppression, leading to better visualization of microvascular architecture.
A new study from Ohio State University suggests that a comprehensive exercise and diet program in a group setting can help prostate cancer patients avoid weight gain and strength loss, reducing the risk of chronic health problems. The study found significant differences between men who participated in the program and those who did not.
Researchers have developed a new technology that can characterize gene expression at the level of individual cells in prostate cancer. The technique uses magnetic nanoparticles to trap and analyze circulating tumor cells, allowing for rapid and accurate detection of biomarkers associated with drug resistance.
A study published in the Journal of Clinical Oncology found that taking a standard prostate cancer drug with food can boost its impact and lower costs. By decreasing the daily dose, preventing digestive issues, and cutting costs by 75 percent, patients could save up to $300,000 per month.
A new approach to analyzing prostate gland tissue uses cellular metabolites to differentiate between aggressive and less aggressive tumors. The study found that metabolite levels can predict tumor grade, stage, and recurrence risk, helping guide treatment strategy.
Researchers discover microRNA molecule miR-940 that alters bone structure in late-stage prostate cancer. The molecule promotes osteoblastic lesions, which can cause severe pain and structural weakness.
A new analysis has found that the PIVOT study's patient population was not representative of real-world patients, with those in the trial being older and sicker. This raises significant questions about the validity of the study's findings and potential treatment recommendations.
A new machine learning model can accurately predict which patients are most likely to benefit from prostate multiparametric MRI (mpMRI), allowing for optimized patient selection and resource allocation. The model showed high accuracy in predicting PI-RADS category 4 or 5 lesions, with a sensitivity of 75% and specificity of 82%.
A study by Tampere University found new prostate cancer mechanisms that are not shown by genomic alterations, including changes in the citric acid cycle. Several potential new biomarkers of prostate cancer were also discovered.
A new study using Medicare claims data found that finasteride significantly reduces prostate cancer risk over a period of 16 years, with a 21% decrease in risk compared to those on a placebo. This long-term benefit is twice as long as previously recorded.
The study found that nearly half of the wives reported that their partner's health problem affected their own health, with many feeling increasingly socially isolated. The women also expressed concerns about the role change in their relationship as their husbands became less able to fulfill their usual roles.
A new study reveals that prostate MRI scans can reduce the number of invasive biopsies by up to 28% and detect more harmful cancers. The results show that using MRI to target biopsies leads to more significant cancer diagnoses, while also reducing unnecessary diagnoses.
A Chinese AI system can diagnose prostate cancer with accuracy comparable to human pathologists, offering potential benefits for streamlining cancer diagnosis and overcoming pathologist shortages. The system was developed using a learning algorithm and showed promise in accurately classifying malignancy levels and Gleason Grades.
A new study published in JAMA Oncology found that higher doses of radiation therapy did not improve survival rates for patients with intermediate-risk prostate cancer. However, the study did show lower rates of recurrence and tumor growth in the group receiving the higher dose, which could lead to better quality of life.
A new systematic review and meta-analysis of previous research found limited data to support the effectiveness of digital rectal exams for prostate cancer screening. The study concluded that existing studies were at risk of bias due to poor quality evidence.